Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol

Cardiology in the Young

Volumn 13, Issue 4, 2003, Pages 333-336

  Giardini, Alessandro ^a   Formigari, Roberto ^a   Bronzetti, Gabriele ^a   Prandstraller, Daniela ^a   Donti, Andrea ^a   Bonvicini, Marco ^a   Picchio, Fernando M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

blockade; Cardiac failure; Cardiomyopathy

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; HOMOVANILLIC ACID; INOTROPIC AGENT; NEUROHORMONE; NORADRENALIN; VANILMANDELIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INFANT; NORADRENALIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ADULT; CONGESTIVE HEART FAILURE; DRUG EFFECT; METABOLISM; PRESCHOOL CHILD;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARBAZOLES; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; INFANT; NEUROTRANSMITTER AGENTS; PROPANOLAMINES; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 2142774040     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951103000672     Document Type: Article

References (22)

1. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001; 110: 81-94.
2. Campbell DJ, Aggarwal A, Esler M, Kaye D. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001; 358: 1609-1610.
3. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
4. Packer M, Antonopulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. Am Heart J 2001; 141: 899-907.
5. Laer S, Mir TS, Behn F, et al. Carvedilol therapy in Pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916-922.
6. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002; 21: 906-909.
7. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: An initial multicenter experience. J Pediatr 2001; 138: 505-511.
8. Azeka E, Franchini Ramirez JA, Valler C, Bochi EA. Delisting of infants and children from heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 10: 2034-2038.
9. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996; 94: 2285-2296.
10. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998; 32 (Suppl 1): S22-S30.
11. Conraads V, Paelinck B, Vorlat A, Goethals M, Jacobs W, Vrints C. Isolated non-compaction of the left ventricle: A rare indication for heart transplantation. J Heart Lung Transplant 2001; 20: 904-907.
12. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83: 39A-42A.
13. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neurohendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-1729.
14. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
15. Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: Relation to pathogenesis of chatecholamine cardiomyopathy. Am Heart J 1981; 102: 210-221.
16. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804.
17. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659-1666.
18. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res 2000; 45: 704-712.
19. Khattar RS, Senior R, Soman P, Van der Does R, Lahiri A. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. Am Heart J 2001; 142: 704-713.
20. Shaddy RE, Curtin EL, Sower B, et al. The pediatric randomized carvedilol trial in children with heart failure: Rationale and design. Am Heart J 2002; 144: 383-389.
21. Buchhorn R, Bartmus D, Siekmeyer W, Hulpke-Wette M, Schulz R, Buersch J. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol 1998; 11: 1366-1368.
22. Buchhorn R, Ross RD, Bartmus D, Wessel A, Hulpke-Wette M, Buersch J. Activity of the renin-angiotensin-aldosterone and sympathetic nervous system and their relation to hemodynamic and clinical abnormalities in infants with left-to-right shunts. Int J Cardiol 2001; 70: 225-230.